Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03775200
Recruitment Status : Recruiting
First Posted : December 13, 2018
Last Update Posted : March 25, 2021
Sponsor:
Information provided by (Responsible Party):
COMPASS Pathways

Tracking Information
First Submitted Date  ICMJE December 11, 2018
First Posted Date  ICMJE December 13, 2018
Last Update Posted Date March 25, 2021
Actual Study Start Date  ICMJE January 1, 2019
Estimated Primary Completion Date May 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 11, 2019)
Montgomery Asberg Depression Rating Scale (MADRS) [ Time Frame: Up to 12 weeks ]
MADRS is a clinician-rated scale measuring depression severity, consisting of 10 items, each scored from 0 (normal) to 6 (severe), for a total possible score of 60; higher scores denote greater severity. Response = >50% decrease and Remission =< 10 actual score.
Original Primary Outcome Measures  ICMJE
 (submitted: December 11, 2018)
MADRS [ Time Frame: Up to 12 weeks ]
MADRS
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Official Title  ICMJE The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
Brief Summary The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression
Detailed Description The Safety and Efficacy of Psilocybin in Participants with Treatment Resistant Depression - a dose-ranging study
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Treatment Resistant Depression
Intervention  ICMJE Drug: Psilocybin
Dose-ranging
Study Arms  ICMJE
  • Experimental: Low dose
    Low dose Psilocybin
    Intervention: Drug: Psilocybin
  • Experimental: Medium dose
    Medium dose Psilocybin
    Intervention: Drug: Psilocybin
  • Experimental: High dose
    High dose Psilocybin
    Intervention: Drug: Psilocybin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: December 11, 2018)
216
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 2021
Estimated Primary Completion Date May 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Diagnosis of TRD

Exclusion Criteria:

  • Other comorbidities
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Susan Stansfield, PhD +44-7780-523013 sue@compasspathways.com
Listed Location Countries  ICMJE Canada,   Czechia,   Denmark,   Germany,   Ireland,   Netherlands,   Portugal,   Spain,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03775200
Other Study ID Numbers  ICMJE COMP001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party COMPASS Pathways
Study Sponsor  ICMJE COMPASS Pathways
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account COMPASS Pathways
Verification Date March 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP